Atara Bio announces publication of phase 1 study demonstrating clinical improvement
Atara Biotherapeutics announced that results of a Phase 1 clinical study were published online in JCI Insight. The article describes clinical findings observed in progressive multiple sclerosis (MS) patients treated with ATA190, Atara’s autologous EBV-specific T-cell immunotherapy. November 19, 2018